**Background**
N-glycosylation is a critical post-translational modification process where carbohydrate chains are attached to proteins, playing a vital role in protein folding, stability, and cell signaling. The STT3A and STT3B subunits are the catalytic cores of the oligosaccharyltransferase (OST) complex, which is responsible for the transfer of the glycan precursor to nascent polypeptide chains. Dysregulation of N-glycosylation is frequently associated with various pathologies, including viral infections, where viruses hijack the host’s glycosylation machinery to facilitate entry and evade the immune system. Furthermore, aberrant glycosylation is a hallmark of many malignancies and neurodegenerative disorders. Consequently, targeting STT3A/B has emerged as a promising strategy for therapeutic intervention. In this context, we will introduce a STT3A/B inhibitor – (R,S)-STT3A/B-IN-1.
**Definition**
(R,S)-STT3A/B-IN-1 is a STT3A/B inhibitor that serves as the racemate of STT3A/B-IN-1. According to the (R,S)-STT3A/B-IN-1 description, this compound is designed to inhibit N-glycosylation to modulate disease progression.
**Mechanism of Action**
The (R,S)-STT3A/B-IN-1 formula is $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_2\text{S}$, with a molecular weight of 355.45. This compound acts by inhibiting the activity of STT3A and STT3B, thereby blocking the N-glycosylation pathway. By disrupting this essential modification, (R,S)-STT3A/B-IN-1 can interfere with the production of functional glycoproteins necessary for viral replication and tumor cell survival.
**Experimental Studies**
Based on the (R,S)-STT3A/B-IN-1 biological activity, this sulfoximine-based modulator demonstrates significant potential in the research of viral diseases, (R,S)-STT3A/B-IN-1 Cancer, and neurodegenerative disorders. By inhibiting the OST complex, the compound effectively reduces the N-glycosylation of target proteins, which is a critical step in the pathogenesis of these conditions. In conclusion, (R,S)-STT3A/B-IN-1 is a promising STT3A/B inhibitor for the study and treatment of various glycosylation-dependent diseases.
Keywords
(R,S)-STT3A/B-IN-1, 3067185-00-3, Drug Isomer, Virus Protease, N-Glycosylation, Inhibitor, inhibitor, inhibit
References